021-51111890
购物车（）
sales@molnova.cn
AZD 7009 B
CAS No. 335619-18-6
AZD 7009 B ( —— )
产品货号. M34517 CAS No. 335619-18-6
AZD 7009 is a novel antiarrhythmic compound that inhibits the sodium current of hNav1.5 in CHO K1 cells with an IC50 of 11 uM. AZD 7009 inhibited late sodium current in isolated rabbit atrial and ventricular myocytes, and prolonged E-4031-induced action potential duration, promoting early post-depolarization of Purkinye fibers (EADs).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥5387 | 有现货 |
|
| 10MG | ￥7249 | 有现货 |
|
| 25MG | ￥10509 | 有现货 |
|
| 50MG | ￥14229 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称AZD 7009 B
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述AZD 7009 is a novel antiarrhythmic compound that inhibits the sodium current of hNav1.5 in CHO K1 cells with an IC50 of 11 uM. AZD 7009 inhibited late sodium current in isolated rabbit atrial and ventricular myocytes, and prolonged E-4031-induced action potential duration, promoting early post-depolarization of Purkinye fibers (EADs).
-
产品描述AZD 7009 is a novel antiarrhythmic compound that inhibits the sodium current of hNav1.5 in CHO K1 cells with an IC50 of 11 uM. AZD 7009 inhibited late sodium current in isolated rabbit atrial and ventricular myocytes, and prolonged E-4031-induced action potential duration, promoting early post-depolarization of Purkinye fibers (EADs).
-
体外实验——
-
体内实验——
-
同义词——
-
通路Membrane Transporter/Ion Channel
-
靶点Sodium Channel
-
受体Sodium Channel
-
研究领域——
-
适应症——
化学信息
-
CAS Number335619-18-6
-
分子量446.54
-
分子式C23H34N4O5
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESC([C@@H](COC1=CC=C(C#N)C=C1)O)N2CC3OC(C2)CN(CCNC(OC(C)(C)C)=O)C3
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
PF-06869206
PF-06869206 是钠-磷酸盐协同转运蛋白 NaPi2a 的口服选择性抑制剂（SLC34A1，IC50：380 nM）。
-
Oxethazaine
Oxethazaine (Oxetacaine) 是芬特明的酸性前体，是一种具有耐酸性和口服活性试剂。Oxethazaine (Oxetacaine) 具有缓解消化性溃疡疾病或食管炎引起的疼痛的潜力。
-
LTGO-33
LTGO-33 is a species-specific inhibitor of the voltage-gated sodium channel NaV1.8, inhibiting NaV1.8, NaV1.1-NaV1.7, and NaV1.9.LTGO-33 inhibits wild-type and multiple NaV1.8 variants associated with human pain disorders and can be used for the study of pain.hBChE-IN-2 is a low affinity Nurr1 agonist.
